Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial

Lancet. 2024 Jul 27;404(10450):337-338. doi: 10.1016/S0140-6736(24)01045-6.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized* / therapeutic use
  • Antineoplastic Agents, Immunological / therapeutic use
  • Breast Neoplasms* / drug therapy
  • Breast Neoplasms* / pathology
  • Camptothecin / administration & dosage
  • Camptothecin / analogs & derivatives
  • Camptothecin / therapeutic use
  • Female
  • Humans
  • Immunoconjugates
  • Neoplasm Metastasis

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Immunological
  • Camptothecin
  • Immunoconjugates
  • sacituzumab govitecan